Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Selvita Extends Collaboration with Chiesi Farmaceutici

Published: Monday, January 13, 2014
Last Updated: Monday, January 13, 2014
Bookmark and Share
Collaboration started with fee-for-service chemical synthesis in 2011.

Selvita has extended its chemistry research collaboration with Chiesi Farmaceutici from Italy.

“We are very proud to be working for such renowned and innovative company as Chiesi. Chiesi projects always involve novel, challenging chemistry and they let us demonstrate the full potential of Selvita’s chemistry team, our broad knowledge, experience and skills.” said Dr Miroslawa Zydron, Director of Contract Chemistry Department at Selvita.

The collaboration between Chiesi and Selvita started with fee-for-service chemical synthesis in 2011. After the successful completion of several projects, it evolved into FTE-based collaboration in 2012-2013.

The joint projects support Chiesi proprietary drug discovery and development pipeline, which is focused on respiratory, cardiovascular and special care disorders.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Selvita Opens New Research Site in Poznan
New site will be located at in the Wielkopolska Centre of Advanced Technologies.
Friday, February 05, 2016
Merck and Selvita Announce Drug Discovery Collaboration
Focus is to discover small molecule lead candidates for multiple oncology indications.
Tuesday, November 03, 2015
Selvita Launches New Company
Bioinformatics and personalized medicine focused Ardigen.
Friday, September 25, 2015
Selvita Establishes its First Operations in the U.S.
The largest drug discovery company in Central and Eastern Europe opens offices in Cambridge, MA and San Bruno, CA.
Saturday, September 19, 2015
Selvita Team Grows to Over 250 People
The company will publish its results for H1 2015 on August 13, 2015.
Tuesday, August 11, 2015
Selvita Establishes its UK Subsidiary in Cambridge
New office will be responsible for supporting the ongoing projects for the UK and Northern Ireland customers.
Thursday, May 07, 2015
Selvita Initiates IND-enabling Studies for its First-In-Class PIM/FLT3 Inhibitor
Company has signed agreement with Aptuit for the preparation of selected studies for the IND/CTA data package.
Saturday, April 04, 2015
Selvita Expands its Proteomics Services Offer
Expansion includes highly sophisticated mass spectrometers, additional ultra HPLC systems; and microscale thermophoresis measurement devices.
Wednesday, March 25, 2015
Selvita Group Received a GMP Certificate
Certificate was issued for 3 years.
Wednesday, February 19, 2014
Selvita Announces Changes to Management Board
Company announces appointment of Dr. Miroslawa Zydron and Dr. Krzysztof Brzozka.
Wednesday, November 06, 2013
Selvita and Orion Pharma Achieve a Research Milestone in Alzheimer’s Disease Program
Selvita is responsible for early research on the program.
Monday, July 02, 2012
Selvita Signs Contract with Evestra
Delivery of a range of drug metabolism, pharmacokinetic and physicochemical studies.
Tuesday, September 27, 2011
Selvita Signs a Computational Chemistry Services Agreement with IPD, USA
Agreement aims to identify novel chemical compounds that inhibit the activity of a novel protein target, proposed by IPD.
Wednesday, April 06, 2011
Selvita Signs a Drug Discovery Services Contract with Rottapharm Madaus
The project is aimed to deliver Rottapharm Madaus a set of designed and synthesized compounds having therapeutic potential in an indicated area.
Thursday, July 22, 2010
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
New NIH-EPA Research Centers to Study Environmental Health Disparities
Scientists will partner with community organizations to study these concerns and develop culturally appropriate ways to reduce exposure to harmful environmental conditions.
Structure of Essential Digestive Enzyme Uncovered
Using a powerful combination of techniques from biophysics to mathematics, researchers have revealed new insights into the mechanism of a liver enzyme that is critical for human health.
Air Pollution Linked to Heart Disease
10-year project revealed air pollutants accelerate plaque build-up in arteries to the heart.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Following Tricky Triclosan
Antibacterial product flows through streams, crops.
Vitamin A May Help Improve Pancreatic Cancer Chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London (QMUL).
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!